Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy.
OBJECTIVE
The study evaluated the relationship between plasma cardiotrophin-1 (CT-1) concentration and left ventricular (LV) mass in dilated cardiomyopathy (DCM) patients with congestive heart failure (CHF).


BACKGROUND
Cardiotrophin-1 is a newly identified member of the interleukin-6 (IL-6) family of cytokines and one of the endogenous ligands for gp130 signaling pathways in the heart, and it has potent hypertrophic and survival effects on cardiac myocytes. However, the clinical significance of CT-1 is poorly understood.


METHODS
We measured the plasma CT-1 level in 51 consecutive patients with DCM. Patients were classified into two groups: small LV mass index group and large LV mass index group, based on the median level of LV mass index.


RESULTS
The plasma CT-1 level was increased in DCM patients with the severity of CHF and was significantly higher in the large LV mass group than in the small LV mass group, despite the absence of a difference in LV ejection fraction between the two groups. In addition, there was a significant positive correlation between the plasma CT-1 level and the LV mass index (r = 0.627, p < 0.0001). According to stepwise multivariate analyses among hemodynamic and neurohumoral factors, a high plasma CT-1 level showed an independent and significant positive relationship with a large LV mass index in patients with DCM.


CONCLUSIONS
These results indicate that the plasma CT-1 level is increased in patients with DCM and is significantly correlated with the LV mass index, suggesting that CT-1 plays an important role in structural LV remodeling in patients with DCM.
Tsutamoto
T
T
First Department of Internal Medicine, Shiga University of Medical Science, Otsu, Japan. tutamoto@belle.shiga-med.ac.jp
Wada
A
A
Maeda
K
K
Mabuchi
N
N
Hayashi
M
M
Tsutsui
T
T
Ohnishi
M
M
Fujii
M
M
Matsumoto
T
T
Yamamoto
T
T
Wang
X
X
Asai
S
S
Tsuji
T
T
Tanaka
H
H
Saito
Y
Y
Kuwahara
K
K
Nakao
K
K
Kinoshita
M
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000804:Angiotensin II / Q000097:blood; D002311:Cardiomyopathy, Dilated / Q000097:blood* / Q000150:complications* / Q000276:immunology; D016022:Case-Control Studies; D016207:Cytokines / Q000097:blood* / Q000502:physiology; D005260:Female; D006333:Heart Failure / Q000145:classification / Q000209:etiology* / Q000473:pathology* / Q000503:physiopathology; D006439:Hemodynamics; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000145:classification / Q000209:etiology* / Q000473:pathology* / Q000503:physiopathology; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009638:Norepinephrine / Q000097:blood; D011237:Predictive Value of Tests; D011863:Radioimmunoassay; D012720:Severity of Illness Index; D015398:Signal Transduction / Q000276:immunology; D013318:Stroke Volume; D020257:Ventricular Remodeling / Q000276:immunology
D016207:Cytokines; D000804:Angiotensin II; C092073:cardiotrophin 1; D009638:Norepinephrine